Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | CFTR | P13569 | 1/20 | 0.32 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | TDP2 | O95551 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4065553 | 0.72 | CFTR (0.37) | ALDH1A1SMN1; SMN2LMNACFTRGOPC | |
| SCHEMBL3004335 | 0.70 | ALDH1A1 (0.40) | AXLALDH1A1SMN1; SMN2LMNACFTR | |
| SCHEMBL27852135 | 0.68 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL27789148 | 0.67 | SIGMAR1 (0.35) | ALDH1A1SMN1; SMN2KDM4EGAAMAPT | |
| SCHEMBL28445481 | 0.67 | KMT2A (0.32) | LMNACFTRGOPCMAPTHTT | |
| SCHEMBL14065284 | 0.66 | AXL (0.39) | AXLALDH1A1SMN1; SMN2LMNACFTR | |
| SCHEMBL19834896 | 0.66 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL3640610 | 0.64 | ALDH1A1 (0.41) | AXLALDH1A1SMN1; SMN2LMNACFTR | |
| SCHEMBL3004434 | 0.64 | BRD4 (0.34) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL27617341 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3458076-B1 | HUMAN AIRWAY STEM CELLS IN LUNG EPITHELIAL ENGINEERING | MASSACHUSETTS GEN HOSPITAL (US) | 2026-03-04 | — | — | EP | disclosed |
| US-12419876-B2 | Treatment of hearing loss by inhibition of casein kinase 1 | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2025-09-23 | — | — | US | disclosed |
| EP-3970725-B1 | A GAMMA SECRETASE INHIBITOR FOR TREATING HEARING LOSS | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2025-08-20 | — | — | EP | disclosed |
| US-20250099539-A1 | METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS AND/OR SUPPORTING CELLS | MASSACHUSETTS EYE AND EAR INFIRMARY | 2025-03-27 | — | — | US | disclosed |
| US-12239651-B2 | Treatment of hearing loss | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2025-03-04 | — | — | US | disclosed |
| US-12161647-B2 | Treating hearing loss | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2024-12-10 | — | — | US | disclosed |
| US-12156899-B2 | Methods and compositions for regenerating hair cells and/or supporting cells | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2024-12-03 | — | — | US | disclosed |
| US-20240299432-A1 | TREATMENT OF HEARING LOSS | MASSACHUSETTS EYE AND EAR INFIRMARY | 2024-09-12 | — | — | US | disclosed |
| US-12043653-B2 | Efficient delivery of therapeutic molecules to cells of the inner ear | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2024-07-23 | — | — | US | disclosed |
| US-11963968-B2 | Treatment of hearing loss | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2024-04-23 | — | — | US | disclosed |
| US-20170327557-A1 | Efficient delivery of therapeutic molecules to cells of the inner ear | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-11-16 | — | — | US | disclosed |
| US-20170326273-A1 | Human Airway Stem Cells in Lung Epithelial Engineering | THE GENERAL HOSPITAL CORPORATION | 2017-11-16 | — | — | US | disclosed |
| EP-3212773-A1 | EFFICIENT DELIVERY OF THERAPEUTIC MOLECULES TO CELLS OF THE INNER EAR | Massachusetts Eye & Ear Infirmary (US) | 2017-09-06 | — | — | EP | disclosed |
| WO-2016069906-A1 | EFFICIENT DELIVERY OF THERAPEUTIC MOLECULES TO CELLS OF THE INNER EAR | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2016-05-06 | — | — | WO | disclosed |
| US-20150209406-A1 | METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS AND/OR SUPPORTING CELLS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2015-07-30 | — | — | US | disclosed |
| US-20150209367-A1 | Treating Hearing Loss | MASSACHUSETTS EYE & EAR INFIRMARY | 2015-07-30 | — | — | US | disclosed |
| US-8188069-B2 | Azepine derivatives as gamma-secretase inhibitors | ELI LILLY AND COMPANY (US) | 2012-05-29 | — | — | US | disclosed |
| US-20100197660-A1 | AZEPINE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2010-08-05 | — | — | US | disclosed |
| EP-2178844-A1 | AZEPINE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS | Eli Lilly & Company (US) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009023453-A1 | AZEPINE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12419876-B2 | Treatment of hearing loss by inhibition of casein kinase 1 | GSK3B, GSKIP, BACE1 | AXL 4701/4885ALDH1A1 3368/4885SMN1; SMN2 3604/4885 |
| US-20170327557-A1 | Efficient delivery of therapeutic molecules to cells of the inner ear | HES1, NOTCH1, NOTCH2 | AXL 4395/4885ALDH1A1 1081/4885SMN1; SMN2 4645/4885 |
| US-20240299432-A1 | TREATMENT OF HEARING LOSS | HES1, NOTCH1, NOTCH4 | AXL 4544/4885ALDH1A1 2645/4885SMN1; SMN2 3919/4885 |
| US-20150209406-A1 | METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS AND/OR SUPPORTING CELLS | HES1, NOTCH1, NOTCH4 | AXL 4778/4885ALDH1A1 2115/4885SMN1; SMN2 4646/4885 |
| US-20100197660-A1 | AZEPINE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS | BACE1, BACE2, PSEN1 | AXL 3227/4885ALDH1A1 2813/4885SMN1; SMN2 1292/4885 |
| US-12161647-B2 | Treating hearing loss | BACE1, BACE2, PSENEN | AXL 4395/4885ALDH1A1 511/4885SMN1; SMN2 3846/4885 |
| US-12043653-B2 | Efficient delivery of therapeutic molecules to cells of the inner ear | HES1, NOTCH1, NOTCH2 | AXL 4395/4885ALDH1A1 1081/4885SMN1; SMN2 4645/4885 |
| US-12156899-B2 | Methods and compositions for regenerating hair cells and/or supporting cells | HES1, NOTCH1, NOTCH4 | AXL 4787/4885ALDH1A1 2172/4885SMN1; SMN2 4643/4885 |
| US-20250099539-A1 | METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS AND/OR SUPPORTING CELLS | HES1, NOTCH1, NOTCH4 | AXL 4787/4885ALDH1A1 2172/4885SMN1; SMN2 4643/4885 |
| US-20150209367-A1 | Treating Hearing Loss | BACE1, BACE2, PSENEN | AXL 4395/4885ALDH1A1 511/4885SMN1; SMN2 3846/4885 |
| US-12239651-B2 | Treatment of hearing loss | HES1, NOTCH1, NOTCH4 | AXL 4544/4885ALDH1A1 2645/4885SMN1; SMN2 3919/4885 |
| US-11963968-B2 | Treatment of hearing loss | HES1, NOTCH1, NOTCH4 | AXL 4544/4885ALDH1A1 2645/4885SMN1; SMN2 3919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.